Therapeutic anticoagulation therapy (OAC)
| Indication | Therapy | Duration of therapy | Guideline |
| Non-valvular atrial fibrillation or atrial flutter with CHA2DS2-VASc ≥2 | DOAC or VKA | Lifelong | 2016 ESC Guidelines for the management of atrial fibrillation.14 |
| Atrial fibrillation >48 hours existing for which cardioversion is indicated and CHA2DS2-VASc <2 | DOAC or VKA | At least 3 weeks prior to cardioversion until 4 week after cardioversion | 2016 ESC Guidelines for the management of atrial fibrillation.14 |
| Venous thromboembolism | DOAC or VKA | 3 months to lifelong | 2016 FMS Antithrombotisch beleid (Antithrombotic policy)15 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society.16 |
| Mechanical valve | VKA | Lifelong | 2017 ESC Guidelines for the management of valvular heart disease.12 |
| Biological mitral of tricuspidal valve <3 months (implantation or reconstruction) | VKA | 3 months, followed by lifelong SAPT | 2017 ESC/EACTS Guidelines for the management of valvular heart disease.10 |
EACTS, European Society of Cardio-Thoracic Surgery; ESC, European Society of Cardiology; FMS, Federatie Medisch Specialisten; VKA, vitamin K antagonists.